LEINFELDEN-ECTERDINGEN, Germany, May 15, 2020 /PRNewswire/ -- VSY Biotechnology GmbH is very excited to announce a new drug, named TR-C 19, has been developed to treat COVID-19 by the VSY Biotechnology R&D team. Studies have shown that TR-C 19 can neutralize the virus isolated under laboratory conditions. Drug is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial. Health authorities accelerate their evaluation of TR-C 19 considering public health emergency conditions.
Dr. Ercan Varlibas, the Chairman of the Board of Directors of VSY Biotechnology GmbH stated that "At VSY Biotechnology, we have completed many pioneering R&D projects by producing new technologies thanks to our R&D team and innovation power. Our TR-C 19 project is one of the most meaningful projects that we have been developing."
Clinical and voluntary trials will be organized in partnership with SBU. The initial results of voluntary patient trials will be shared publicly in the coming weeks.
About VSY Biotechnology GmbH
VSY Biotechnology GmbH is an innovation driven company with its progressive R&D activities in ophthalmology, orthopedics, aesthetics and biotechnologic drugs. VSY Biotechnology focuses on developing, designing and manufacturing superior state-of-the-art products to serve doctors, patients and consumers beyond their expectations.